Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

14.66
-0.1400-0.95%
Volume:122.52K
Turnover:1.78M
Market Cap:227.45M
PE:-4.59
High:14.74
Open:14.68
Low:14.45
Close:14.80
52wk High:16.77
52wk Low:13.06
Shares:15.52M
Float Shares:11.14M
Volume Ratio:0.87
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1910
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:-3.63
PE(LYR):-4.59

Loading ...

BRIEF-Novartis Said To Near $70-Per-Share-Plus Deal For Avidity-Bloomberg News

Reuters
·
Oct 26, 2025

Novartis Said to Near $70-per-Share-Plus Deal for Avidity-Bloomberg News

THOMSON REUTERS
·
Oct 26, 2025

Avidity Biosciences Chief Medical Officer Steven George Hughes Reports Disposal of Common Shares

Reuters
·
Oct 25, 2025

CSPC PHARMA (01093): SYH2061 Injection (Dual-Chain Small Interfering RNA Drug) Approved for Clinical Trials in China

Stock News
·
Oct 24, 2025

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

GlobeNewswire
·
Oct 20, 2025

Avidity Biosciences Inc. Chief Human Resources Officer Teresa McCarthy Reports Disposal of Common Shares

Reuters
·
Oct 18, 2025

Avidity Biosciences Delays Biologics License Application

TIPRANKS
·
Oct 14, 2025

Avidity Biosciences Showcases Advancements in RNA Therapeutics and Progress Toward Commercializing Rare Neuromuscular Disease Treatments

Reuters
·
Oct 14, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

Reuters
·
Oct 14, 2025

BUZZ-Avidity rises on plans to submit muscle wasting drug application to US FDA

Reuters
·
Oct 13, 2025

BRIEF-Avidity Biosciences Announces Positive Pre-BLA Meeting With US FDA For del-zota In DMD44

Reuters
·
Oct 13, 2025

Avidity Biosciences Announces Positive Pre-Bla Meeting With U.S. FDA for Del-Zota in Dmd44 With a Submission Planned for Q1 2026

THOMSON REUTERS
·
Oct 13, 2025

Avidity Biosciences Inc - Bla Submission for Del-Zota Updated to Q1 2026

THOMSON REUTERS
·
Oct 13, 2025

ProQR to Participate in Upcoming Investor Conferences in October 2025

GlobeNewswire
·
Oct 13, 2025

Press Release: Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

Dow Jones
·
Oct 10, 2025

Avidity Biosciences (RNA) Is Up 12.2% After Positive DMD Therapy Data Revealed at WMS Congress – Has The Bull Case Changed?

Simply Wall St.
·
Oct 09, 2025

CSPC PHARMA (01093): SYH2070 Injection (Double-Stranded Small Interfering RNA Drug) Receives Clinical Trial Approval in the United States

Stock News
·
Oct 09, 2025

Avidity Biosciences’ Phase 2 Study on AOC 1001: A Potential Game-Changer for DM1 Treatment

TIPRANKS
·
Oct 09, 2025